Evidence map›Paper›PMID 38873254›Full record

ArticleFrontiers in oncology2024

Risk score model to automatically detect prostate cancer patients by integrating diagnostic parameters.

Rossana Castaldo, Valentina Brancato, Carlo Cavaliere, Leandro Pecchia, Ester Illiano, Elisabetta Costantini, Alfonso Ragozzino, Marco Salvatore, Emanuele Nicolai, Monica Franzese

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rossana CastaldoBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.
Valentina BrancatoBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.
Carlo CavaliereBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.
Leandro PecchiaSchool of Engineering, University of Warwick, Coventry, United Kingdom.
Ester IllianoAdrology and Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni, Italy.
Elisabetta CostantiniAdrology and Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni, Italy.
Alfonso RagozzinoBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.
Marco SalvatoreBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.
Emanuele NicolaiBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.
Monica FranzeseBioinformatics and Biostatistics Lab, IRCCS SYNLAB SDN, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prostate cancer (PCa) is one of the prevailing forms of cancer among men. At present, multiparametric MRI is the imaging method for localizing tumors and staging cancer. Radiomics plays a key role and hold potential for PCa detection, reducing the need for unnecessary biopsies, characterizing tumor aggression, and overseeing PCa recurrence post-treatment. Methods: Furthermore, the integration of radiomics data with clinical and histopathological data can further enhance the understanding and management of PCa and decrease unnecessary transfers to specialized care for expensive and intrusive biopsies. Therefore, the aim of this study is to develop a risk model score to automatically detect PCa patients by integrating non-invasive diagnostic parameters (radiomics and Prostate-Specific Antigen levels) along with patient's age. Results: The proposed approach was evaluated using a dataset of 189 PCa patients who underwent bi-parametric MRI from two centers. Elastic-Net Regularized Generalized Linear Model achieved 91% AUC to automatically detect PCa patients. The model risk score was also used to assess doubt cases of PCa at biopsy and then compared to bi-parametric PI-RADS v2. Discussion: This study explored the relative utility of a well-developed risk model by combining radiomics, Prostate-Specific Antigen levels and age for objective and accurate PCa risk stratification and supporting the process of making clinical decisions during follow up.

Indexed as

machine learningMRIprostate cancerradiomicsrisk score

Identifiers

PMID38873254
PMCPMC11171723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.